Immunome's COVID-19 antibody cocktail back on track for phase 1 after FDA lifts hold

Immunome’s antibody cocktail COVID-19 treatment is free from an FDA hold, two months after the pause was first placed.

In January, the FDA told the company to slow its roll and requested more information on the preparation and administration of IMM-BCP-01 at clinical sites. Immunome can now move forward with human trials after providing the agency with a "comprehensive report" with the requested information, according to a Friday press release.